MicroRNA-26 Family in Human Diseases: Context-Dependent Regulation, Biomarker Potential, and Preclinical Nano-Delivery Strategies
- 1Department of Neurosurgery, The Affiliated Hospital, Inner Mongolia Medical University, Hohhot, 010050, People’s Republic of China
- 2Inner Mongolia Medical College Graduate School (Jinshan Campus), Jinshan Economic and Technological Development Zone, Tuzuo Banner, Hohhot, Inner Mongolia, 010110, People’s Republic of China
- 3Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People’s Republic of China
Abstract
Purpose: This review aims to summarize the expression patterns, molecular mechanisms, and preclinical nanodelivery strategies of microRNA-26 (miR-26) family members, and to critically evaluate their potential as biomarker candidates and preclinical therapeutic targets in human diseases, including cancers, cardiovascular diseases, metabolic disorders, and neurodegenerative conditions.
Methods: A structured narrative review was performed in PubMed, Web of Science, Scopus, and Google Scholar from database inception to August 2026. Peer-reviewed original articles and reviews in English were included. Data on miR-26 isoform expression, target genes, signaling pathways, therapeutic modulators, and nanocarrier systems were extracted and narratively synthesized. A four-tier evidence classification system (Levels I–IV) was applied to distinguish well-established findings from speculative or inferred associations.
Results: miR-26 family members—predominantly miR-26a-5p and miR-26b-5p—are highly conserved small non-coding RNAs that post-transcriptionally regulate proliferation, differentiation, apoptosis, metabolism, and immunity in an isoform-specific and context-dependent manner. In most solid tumors, miR-26a-5p and miR-26b-5p are downregulated and function as tumor suppressors, although context-dependent oncogenic roles exist. Circulating and tissue miR-26 isoform levels show statistically significant associations with diagnosis, prognosis, and treatment response in several cancers, supporting their utility as biomarker candidates. However, direct miR-26 mimics or inhibitors remain exclusively preclinical, with no human clinical trials initiated to date. Lipid-, polymer-, and inorganic-based nanocarriers are being explored in preclinical models, but their precision, safety, and biodistribution require systematic validation. Clinical-stage agents targeting downstream effectors of miR-26-regulated pathways do not constitute direct miR-26 modulation and should not be presented as miR-26 therapeutics.
Conclusion: miR-26 family members serve as versatile regulatory hubs and biologically plausible biomarker and preclinical therapeutic target candidates. At present, miR-26 should be viewed primarily as a validated biomarker associate and a promising preclinical target—not as an established therapeutic modality. CRISPRa, microbiome–miR-26 interactions, and AI-assisted nanorobots remain future hypotheses rather than established translational strategies.
Related
- Burnout- and Depression-Like Functional Collapse States — A Within-Person Biomarker Framework for Precision Psychiatry: State-Dependent Multisystem Regulation in High Processing Cost Phenotypes (HPCPh)
- Preclinical-Clinical Discrepancies in Immune Checkpoint Inhibitor Efficacy for Triple-Negative Breast Cancer: Disease Stage, Antibody Properties, Biomarker Alignment, and Model Limitations.
- Pharmacological strategies to manage oxidative stress in Huntington’s disease: from preclinical models to clinical trials
- Strategies of mechanical adaptations of circulating tumor cells and properties of their cellular microenvironment have predictive and prognostic biomarker value
- Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217–based assessment of CSF amyloid positivity in secondary-care patients with MCI
BibTeX
@article{wang2026microrna26,
title = {{MicroRNA-26 Family in Human Diseases: Context-Dependent Regulation, Biomarker Potential, and Preclinical Nano-Delivery Strategies}},
author = {Ruijun Wang and Rile Ge and Zhiqi Li and Zhanbiao He and Yuanming Pan and Xiangdong Zhao},
journal = {International Journal of Nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s642611},
url = {https://doi.org/10.2147/ijn.s642611},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - MicroRNA-26 Family in Human Diseases: Context-Dependent Regulation, Biomarker Potential, and Preclinical Nano-Delivery Strategies
AU - Ruijun Wang
AU - Rile Ge
AU - Zhiqi Li
AU - Zhanbiao He
AU - Yuanming Pan
AU - Xiangdong Zhao
PY - 2026
DA - 2026/10/30
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s642611
UR - https://doi.org/10.2147/ijn.s642611
AB - Purpose: This review aims to summarize the expression patterns, molecular mechanisms, and preclinical nanodelivery strategies of microRNA-26 (miR-26) family members, and to critically evaluate their potential as biomarker candidates and preclinical therapeutic targets in human diseases, including cancers, cardiovascular diseases, metabolic disorders, and neurodegenerative conditions. Methods: A structured narrative review was performed in PubMed, Web of Science, Scopus, and Google Scholar from database inception to August 2026. Peer-reviewed original articles and reviews in English were included. Data on miR-26 isoform expression, target genes, signaling pathways, therapeutic modulators, and nanocarrier systems were extracted and narratively synthesized. A four-tier evidence classification system (Levels I–IV) was applied to distinguish well-established findings from speculative or inferred associations. Results: miR-26 family members—predominantly miR-26a-5p and miR-26b-5p—are highly conserved small non-coding RNAs that post-transcriptionally regulate proliferation, differentiation, apoptosis, metabolism, and immunity in an isoform-specific and context-dependent manner. In most solid tumors, miR-26a-5p and miR-26b-5p are downregulated and function as tumor suppressors, although context-dependent oncogenic roles exist. Circulating and tissue miR-26 isoform levels show statistically significant associations with diagnosis, prognosis, and treatment response in several cancers, supporting their utility as biomarker candidates. However, direct miR-26 mimics or inhibitors remain exclusively preclinical, with no human clinical trials initiated to date. Lipid-, polymer-, and inorganic-based nanocarriers are being explored in preclinical models, but their precision, safety, and biodistribution require systematic validation. Clinical-stage agents targeting downstream effectors of miR-26-regulated pathways do not constitute direct miR-26 modulation and should not be presented as miR-26 therapeutics. Conclusion: miR-26 family members serve as versatile regulatory hubs and biologically plausible biomarker and preclinical therapeutic target candidates. At present, miR-26 should be viewed primarily as a validated biomarker associate and a promising preclinical target—not as an established therapeutic modality. CRISPRa, microbiome–miR-26 interactions, and AI-assisted nanorobots remain future hypotheses rather than established translational strategies.
SN - 1176-9114
SN - 1178-2013
ER -